Favorable benefit-risk ratio with teriflunomide treatment in relapsing-remitting multiple sclerosis: Results of the 2-year, multicenter, prospective, noninterventional TAURUS MS study in Austria.

Also, the mean global satisfaction score showed an increasing trend of 9.4 (SD, 26.5; n = 8; median: 0, IQR: 37.5, min: 21.4, max: 57.1) between baseline and the last visit.

also in 63,971 other papers

Patient treatment satisfaction: The physicians' view The physician ratings of the treatment satisfaction of the patient also failed to reach significance, but they do at least indicate sustained improvements on treatment with teriflunomide.

also in 4,113 other papers